среда, 29 июня 2011 г.

Synthesis of Danusertib


M.Wt: 474.55
Formula: C26H30N6O3
CAS No.: 827318-97-8
PHA-739358 (Danusertib) is a pyrrolopyrazole and small molecule Aurora kinases and Bcr-Abl kinase inhibitor with IC50 of 13, 79, and 61 nM for Aurora A, B, and C, respectively.
High activity was also observed against kinases known to be mutated or over expressed in different cancers such as Ret, Trk-A, and Abl (∼2-fold higher IC50 compared with Aurora A). Cross-reactivity with FGFR-1 was seen at a 4-fold higher IC50 compared with Aurora A. However, in another study, its specificity was tested in vitro against a broad panel of kinases representative of different kinase families. It was shown to be a potent inhibitor of all three Aurora kinases with IC50s of 27, 135, and 120 nM for Aurora A, B, and C, respectively.
Cortes-Franco J, Dombret H, Schafhausen P, et al. Danusertib hydrochloride (PHA-739358), a multi-kinase aurora inhibitior, elicits clinical benefit in advanced chronic myeloid leukemia and Philadelphia chromosome positive acute lymphoblastic leukemia. Blood. 2009,114, 356.

Комментариев нет:

Отправить комментарий

Ярлыки

акситиниб (1) Бринатиниб (1) ваталаниб (1) Гефитиниб (1) гливек (1) дазатиниб (2) данусертиб (1) зактима (1) икотиниб (1) карнетиниб (1) Кризотиниб (1) куизартиниб (1) лапатиниб (1) лекарства (1) лекарство (1) линифаниб (1) Маситиниб (1) нексавар (1) понатиниб (1) руксолитиниб (1) сорафениб (1) спрайсел (2) Сунитиниб (2) сутент (1) тайверб (1) тандуниб (1) Тарцева (2) Цедираниб (1) Эрлотиниб (2) AB1010 (1) ABT-869 (1) Afatinib (2) AG-013736 (1) ALK-kinase (1) AMG-706 (1) AP24534 (1) Apatinib (1) Armala (1) AV-951 (1) axinitib (1) AZD-0530 (1) AZD2171 (2) Bafenitib (1) Bafetinib (2) BAY 73-4506 (1) BIBW 2992 (1) BMS-540215 (2) bosutinib (2) Brivanib (2) canertinib (1) Cediranib (2) CEP-701 (1) CHIR258 (1) CP690550 (1) Crizotinib (1) danusertib (1) Dasatinib (2) Dovitinib (1) Erlotinib (1) Foretinib (1) Gefinitib (1) Gefitinib (2) gleevec (1) Gold reagent (1) HKI 272 (1) Icotinib (1) imatinib (1) INNO-406 (2) Iressa (1) lapatinib (2) lestaurtinib (1) linifanib (1) Masitinib (1) MLN 518 (1) Mubritinib (2) Nexavar (2) nilotinib (1) NS-187 (2) OSI-774 (1) Palladia (1) Pazopanib (2) Pelitinib (1) PF-02341066 (1) PHA-739358 (1) Ponatinib (1) pyrazole (1) Recentin (2) Regorafenib (1) Ruxolitinib (1) Saracatinib (2) sc-202353 (1) Silimitasertib (1) SKI-606 (2) Sorafenib (2) Sorafenib tosylate (1) Sprycel (2) Sunitinib (2) Sunitinib Malate (2) Sutent (2) Tarceva (2) targeted agents (1) tasigna (1) Tasocitinib (1) Tivozanib (1) TKI-258 (1) toceranib (1) Tovok (2) tykerb (2) tyverb (1) vandetanib (1) Vatalanib (1) Votrient (2) YN968D1 (1) zactima (1) ZD6474 (1) 凡德他尼 (1) 尼罗替尼 (1) 阿西替尼 (1)